

For Immediate Release
March 12, 2007

Contact: Mr. Tony Moses
510.933.7600

NeoVista, Inc. Reports Positive 6 Month Concomitant Study Results on Wet AMD therapy

NeoVista, Inc. sees positive results from NVI-111 Study (concomitant radiation/Anti-VEGF) for the treatment of wet Age-Related Macular Degeneration

FREMONT, CA (PRWeb) March 12, 2007 – Data presented today at the Vail Vitrectomy 2007 Meeting in Vail, Colorado highlighted the potential benefit of treating wet Age-Related Macular Degeneration (AMD) with the Epi-Rad₉₀[™] Ophthalmic System, manufactured by NeoVista, Inc.

Six month clinical data was presented from the NeoVista, Inc, sponsored Concomitant Study, which utilized intravitreal 24 Gy Strontium-90 beta radiation, plus initial treatment with the Anti-VEGF agent, Avastin[®]. This study was conducted in ophthalmic centers in Mexico and Brazil. At six months, 45% of the patients treated per protocol achieved ≥ 3 lines of visual acuity gain. This compares favorably to the results obtained in the MARINA Trial, which utilized 0.5 mg of Lucentis[®] alone. In addition, all patients treated in this study achieved a mean change in visual acuity of 13.4 letters at 6 months, which compares favorably to the reported 6.5 letter gain at month six of the MARINA Trial.

Dr. Eugene de Juan, Jr., the Jean Kelly Stock Professor of Ophthalmology at UCSF and a co-inventor of the NeoVista technology, commented, “I believe a surgical approach to managing this dreadful disease is viable. Radiation has been utilized in ophthalmology for many years and the intraocular delivery technique of this minimally invasive procedure appears to be safe and well tolerated by the patient.”

“Our prior study, which utilized 24 Gy of Strontium-90 beta radiation alone, is out to almost 15 months of follow-up, and the data continues to be positive,” stated John N. Hendrick, President and CEO of NeoVista. “We will soon begin our pivotal CABERNET trial incorporating the concomitant use of Lucentis and Epi-Rad₉₀ therapy. We believe that this treatment approach may provide maximum benefit to those suffering from this terrible disease.”

About NeoVista, Inc.

NeoVista, Inc. is a privately held development stage medical device company based in Fremont, CA. The Company intends to enter into a definitive clinical study to support filing for regulatory approval to market the product in the U.S.

For more information, please visit the company website at www.neovistainc.com